FPI-1434, a novel, targeted alpha therapeutic (TAT), consists of an anti-IGF-1R humanized monoclonal antibody (mAb, FPI-1157, formerly AVE1642), a proprietary bifunctional chelate, and an 伪-emitting radionuclide, actinium-225. FPI-1547 is the indium-111 imaging analogue of FPI-1434 and is...
Fusion还与默克(Merck)合作，评估FPI-1434与默克的KEYTRUDA®(pembrolizumab)在表达IGF-1R的实体瘤患者中的联合应用。为了支持Fusion不断增长的TAT管线，该公司已与TRIUMF、Niowave公司和BWXT Medical公司签署了锕供应战略协议。
225Ac标记放射性治疗药物注册临床试验一览表 备注:-2024年3月,阿斯利康以24亿美元收购核药企业FusionPharma的放射性药物产品线,包括管线FPI-2265,用于治疗去势抵抗前列腺癌转移性前列腺癌(mCRPC); -2018年10月,诺华以21亿美元收购Endocyte,获得Endocyte小分子靶向放疗前列腺癌药物177Lu-PSMA-617; -2023年12月,BMS以41...
The aim of this phase 1 study (NCT03746431) is to evaluate the safety and tolerability of [111In]-FPI-1547 and [225Ac]-FPI-1434 in patients with advanced refractory solid tumors and to determine the Recommended Phase 2 Dose (RP2D) of [225Ac]-FPI-1434 in patients with IGF-1R ...